Clinical Trials

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.

A new cancer drug using DNA fragments to deliver chemotherapy more safely has been cleared for US trials, offering hope for less toxic treatments.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Ascentage Pharma's next-gen BTK degrader, APG-3288, receives dual IND clearance, paving the way for clinical trials to fight resistant blood cancers.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

TransCode Therapeutics and Quantum Leap are targeting hidden cancer cells with a novel RNA drug in a pivotal trial that could prevent colorectal cancer relapse.

For the third consecutive year, Virginia Cancer Specialists has been named the top practice in Virginia. We explore how they achieved this sustained success.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.